336 related articles for article (PubMed ID: 33277983)
1. The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model.
Marinov AD; Wang H; Bastacky SI; van Puijenbroek E; Schindler T; Speziale D; Perro M; Klein C; Nickerson KM; Shlomchik MJ
Arthritis Rheumatol; 2021 May; 73(5):826-836. PubMed ID: 33277983
[TBL] [Abstract][Full Text] [Related]
2. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples.
Reddy V; Klein C; Isenberg DA; Glennie MJ; Cambridge G; Cragg MS; Leandro MJ
Rheumatology (Oxford); 2017 Jul; 56(7):1227-1237. PubMed ID: 28407142
[TBL] [Abstract][Full Text] [Related]
3. Depletion of B cells in murine lupus: efficacy and resistance.
Ahuja A; Shupe J; Dunn R; Kashgarian M; Kehry MR; Shlomchik MJ
J Immunol; 2007 Sep; 179(5):3351-61. PubMed ID: 17709552
[TBL] [Abstract][Full Text] [Related]
4. Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
Skopelja-Gardner S; Jones JD; Hamilton BJ; Danilov AV; Rigby WFC
J Immunol; 2017 Aug; 199(4):1275-1282. PubMed ID: 28710251
[TBL] [Abstract][Full Text] [Related]
5. B cell and/or autoantibody deficiency do not prevent neuropsychiatric disease in murine systemic lupus erythematosus.
Wen J; Doerner J; Chalmers S; Stock A; Wang H; Gullinello M; Shlomchik MJ; Putterman C
J Neuroinflammation; 2016 Apr; 13(1):73. PubMed ID: 27055816
[TBL] [Abstract][Full Text] [Related]
6. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus.
Md Yusof MY; Shaw D; El-Sherbiny YM; Dunn E; Rawstron AC; Emery P; Vital EM
Ann Rheum Dis; 2017 Nov; 76(11):1829-1836. PubMed ID: 28684557
[TBL] [Abstract][Full Text] [Related]
7. Internalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosus.
Reddy V; Cambridge G; Isenberg DA; Glennie MJ; Cragg MS; Leandro M
Arthritis Rheumatol; 2015 May; 67(8):2046-55. PubMed ID: 25916583
[TBL] [Abstract][Full Text] [Related]
8. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
Chalmers SA; Glynn E; Garcia SJ; Panzenbeck M; Pelletier J; Dimock J; Seccareccia E; Bosanac T; Khalil S; Harcken C; Webb D; Nabozny G; Fine JS; Souza D; Klein E; Herlitz L; Ramanujam M; Putterman C
Clin Immunol; 2018 Dec; 197():205-218. PubMed ID: 30339790
[TBL] [Abstract][Full Text] [Related]
9. An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in Lupus.
Ahuja A; Teichmann LL; Wang H; Dunn R; Kehry MR; Shlomchik MJ
J Immunol; 2011 Oct; 187(7):3888-94. PubMed ID: 21873531
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody therapy that targets phospholipid-binding protein delays lupus activity in MRL/lpr mice.
Mihaylova N; Bradyanova S; Chipinski P; Chausheva S; Kyurkchiev D; Tchorbanov AI
Scand J Immunol; 2020 Sep; 92(3):e12915. PubMed ID: 32533866
[TBL] [Abstract][Full Text] [Related]
11. A benzenediamine derivative fc-99 attenuates lupus-like syndrome in MRL/lpr mice related to suppression of pDC activation.
Ji J; Fan H; Li F; Li X; Dong G; Gong W; Song Y; Liu F; Hua C; Tan R; Dou H; Hou Y
Immunol Lett; 2015 Dec; 168(2):355-65. PubMed ID: 26545567
[TBL] [Abstract][Full Text] [Related]
12. Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.
Keil A; Hall SR; Körner M; Herrmann M; Schmid RA; Frese S
Arthritis Res Ther; 2016 Oct; 18(1):243. PubMed ID: 27770825
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab.
Yasuhiro T; Sawada W; Klein C; Kozaki R; Hotta S; Yoshizawa T
Leuk Lymphoma; 2017 Mar; 58(3):699-707. PubMed ID: 27684575
[TBL] [Abstract][Full Text] [Related]
14. Y27, a novel derivative of 4-hydroxyquinoline-3-formamide, prevents the development of murine systemic lupus erythematosus-like diseases in MRL/lpr autoimmune mice and BDF1 hybrid mice.
Xiao ZY; Chen SH; Cheng JP; Zhou WX; Zhang YX; Yang RF; Yun LH
Arthritis Res Ther; 2012 Nov; 14(6):R235. PubMed ID: 23116248
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of non-depleting anti-CD4 in MRL/Mp-lpr/lpr mice with active systemic lupus erythematosus and microscopic angiitis.
Harper JM; Cook A
Autoimmunity; 2001; 33(4):245-51. PubMed ID: 11683399
[TBL] [Abstract][Full Text] [Related]
16. B cell depletion with anti-CD79 mAbs ameliorates autoimmune disease in MRL/lpr mice.
Li Y; Chen F; Putt M; Koo YK; Madaio M; Cambier JC; Cohen PL; Eisenberg RA
J Immunol; 2008 Sep; 181(5):2961-72. PubMed ID: 18713966
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of EZH2 Ameliorates Lupus-Like Disease in MRL/lpr Mice.
Rohraff DM; He Y; Farkash EA; Schonfeld M; Tsou PS; Sawalha AH
Arthritis Rheumatol; 2019 Oct; 71(10):1681-1690. PubMed ID: 31106974
[TBL] [Abstract][Full Text] [Related]
18. 4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice.
Kulkarni OP; Sayyed SG; Kantner C; Ryu M; Schnurr M; Sárdy M; Leban J; Jankowsky R; Ammendola A; Doblhofer R; Anders HJ
Am J Pathol; 2010 Jun; 176(6):2840-7. PubMed ID: 20413687
[TBL] [Abstract][Full Text] [Related]
19. Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice.
Yan SX; Deng XM; Wang QT; Sun XJ; Wei W
Acta Pharmacol Sin; 2015 Nov; 36(11):1367-76. PubMed ID: 26456588
[TBL] [Abstract][Full Text] [Related]
20. Anti-ANX A1 Antibody Therapy in MRL/lpr Murine Model of Systemic Lupus Erythematosus.
Bradyanova S; Mihaylova N; Chipinski P; Manassiev Y; Herbáth M; Kyurkchiev D; Prechl J; Tchorbanov AI
Arch Immunol Ther Exp (Warsz); 2021 Jul; 69(1):19. PubMed ID: 34322760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]